NEW YORK, March 25, 2015 /PRNewswire/ -- S&P
Capital IQ (MHFI) announced today that it has commenced Factual
Stock Report coverage on Abattis Bioceuticals Corp.
Abattis Bioceuticals (OTCQX: ATTBF; CSE: ATT): is a specialty
biotechnology company with capabilities through its wholly owned
subsidiaries of cultivating, licensing and marketing proprietary
ingredients, bio-similar compounds, patented equipment and
consulting services to medicinal markets in North America. The company seeks to capitalize
on the current trend toward marijuana legalization in the United States and for medicinal use in
Canada and international
jurisdictions, by supplying and partnering with companies to employ
its mass cultivation systems, extraction equipment/technology, and
strategic marketing support to licensed growers. Abattis also has
an extensive pipeline of products and intellectual property for the
botanical drug market.
Abattis' intellectual property and activities encompass cannabis
cultivation, production, extraction and refining technologies,
quality control and laboratory analysis services, patient payment
technologies and several derivative products.
The company specializes in a number of areas, including medical
marijuana, cannabis cultivation, marijuana dispensary payment
system, high yield marijuana growing, quality control testing 502,
refined marijuana CBD oil, THC extract oil, CBD extract oil, CBD
extraction equipment, CO2 super critical, cannabinoid extracts,
butane honey oil extracts, licensed producer, pre-paid patient
card, medical marijuana phone app, and controlled cultivation
environment.
Abattis owns several subsidiaries with varying capabilities.
Biocube Green Grow Systems Corp., a wholly owned subsidiary of
Abattis, provides controlled cannabis cultivation environments for
high yield marijuana growing. Biocube has exclusive worldwide
rights to a building product derived from magnesium oxide known as
MgO board, which has applications in all areas of the building and
construction industry as a fireproof, antimicrobial, antibacterial,
waterproof, and recyclable material.
iJuana Cannabis Inc., a wholly owned subsidiary of Abattis, aims
to become the licensed cannabis growing arm and consumer-facing
entity for the company.
BioCell Labs Inc., another wholly owned subsidiary of Abattis,
is focused on supplying standardized pharmaceutical grade products.
BioCell leases a botanical drug facility that it will use to
perform quality testing and refining using its proprietary Flash
Freeze Extraction (FFE) and water extraction technologies. It has
13 proprietary formulations for out-licensing to cosmetic,
nutraceutical and pharmaceutical companies.
North American BioExtracts Inc., the wholly owned retail
distribution arm of Abattis, operates in Canada and Washington State. It will focus on cannabis,
cannabis derivatives, and ancillary products like vaporizers where
legally permitted. The subsidiary aims to use its proprietary
extraction technologies to develop customized THC extract oils and
CBD extract oils, as well as customized vaporizer flavors to
enhance the end user's experience.
Northern Vine Canada Inc. has applied for a Controlled Substance
License with Health Canada, with an existing cannabis processing,
testing, and packaging facility located in Langley, British Columbia. In addition to
these services, Northern Vine will support its operations by
providing analytical services for licensed producers and charging a
fee to produce a certificate of analysis. The firm will also
formulate compositions for sprays, creams, and tinctures that it
plans to patent.
On May 21, 2014, Abattis had
leased a 16,200-square-foot facility zoned for medical marijuana
near Vancouver, British Columbia
with the potential to expand to up to 254,000 square feet. On
February 21, 2014, Biocube acquired
the Exclusive World Wide Distribution Rights to Jiangsu Jiahui New
Material Co Ltd.'s innovative MgO (Magnesium Oxide) products for
use in any building or facility designed to cultivate botanicals.
The term of the exclusivity is 5 years. On March 31, 2014, the company incorporated a wholly
owned subsidiary Abattis Bioceuticals International Inc. in
the United States. On March 12, 2014, Abattis sent its newly designed
Biocube drawings to China to have
its first order produced.
On January 16, 2014, the company
was added to The Marijuana Index™. The Index's
website, mmj-index.com, states: This is the first and only
registered equity tracking index which monitors the performance,
news and general pulse of qualified marijuana stocks or cannabis
stocks.
S&P Capital IQ's Factual Stock Report coverage on Abattis
Bioceuticals Corp will also be accessible on an ongoing basis to
the investment community by scores of buy-side institutions and
sell-side firms that utilize S&P Capital IQ research and
information platforms daily. Millions of self-directed investors
also have access to the report via their e-brokerage accounts.
Please visit http://www.abattis.com/ for additional
information.
About S&P Capital IQ's Factual Stock Reports
Currently profiling approximately 400 issuers, S&P Capital
IQ (MHFI) Factual Stock Reports increase market awareness of
issuers in the investment community with insightful commentary, key
statistics, and relevant corporate information. The Reports
provide factual research coverage about company fundamentals and
business prospects, thereby enabling information on the covered
companies to reach a wide spectrum of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other
data, the Reports also capture recent company developments, a
financial review, key operating information, industry and peer
comparisons, Street Consensus, performance charts, business
summary, fundamental data, and timely news stories. Coverage of
these reports is underwritten by the issuer, therefore S&P
Capital IQ does not offer investment opinions concerning the
advisability of investing in these stocks.
S&P Capital IQ Factual Stock Reports are produced separately
from any other analytic activity of S&P Capital IQ or related
organizations. S&P Capital IQ does not trade on its own
account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial (NYSE:MHFI),
is a leading provider of multi-asset class and real time data,
research and analytics to institutional investors, investment and
commercial banks, investment advisors and wealth managers,
corporations and universities around the world. S&P Capital IQ
provides a broad suite of capabilities designed to help track
performance, generate alpha, and identify new trading and
investment ideas, and perform risk analysis and mitigation
strategies. Through leading desktop solutions such as the S&P
Capital IQ, Global Credit Portal and MarketScope Advisor desktops;
enterprise solutions such as S&P Capital IQ Valuations; and
research offerings, including Leveraged Commentary & Data,
Global Markets Intelligence, and company and funds research,
S&P Capital IQ sharpens financial intelligence into the wisdom
today's investors need. For more information, visit
www.spcapitaliq.com.
In the United States, research
reports are prepared by Standard & Poor's Investment Advisory
Services LLC, a part of S&P Capital IQ and a registered
investment adviser with the U.S. Securities and Exchange
Commission. S&P Capital IQ provides a broad suite of
capabilities designed to help track performance, generate alpha,
and identify new trading and investment ideas, and perform risk
analysis and mitigation strategies.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sp-capital-iq-initiates-coverage-on-abattis-bioceuticals-corp-in-sp-capital-iq-factual-stock-reports-300056089.html
SOURCE S&P Capital IQ
